Long-acting &beta;2-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety

Long-acting &beta;2-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety

Andrea Rossi1, Sonia Khirani1, Mario Cazzola21Unit of Respiratory Diseases, Hospital of Bergamo, Bergamo, Italy; 2Unit of Respiratory Diseases, Department of Internal Medicine, University of Rome &lsquo;Tor Vergata&rsquo;, Rome, ItalyAbstract: COPD is characterized by progressive air...

Full description

Bibliographic Details
Main Authors:	Andrea Rossi, Sonia Khirani, Mario Cazzola
Format:	Article
Language:	English
Published:	Dove Medical Press 2008-07-01
Series:	International Journal of COPD
Online Access:	http://www.dovepress.com/long-acting-betasub2sub-agonists-laba-in-chronic-obstructive-pulmonary-a1863

Similar Items

Ultra Long-Acting β-Agonists in Chronic Obstructive Pulmonary Disease
by: Burkes RM, et al.
Published: (2020-12-01)

ARE INHALED LONG-ACTING BETA-AGONISTS (LABA) REALLY HARMFUL IN ADULT ASTHMATICS?
by: TNEW CL, et al.
Published: (2008-01-01)

The safety of long-acting &szlig;2-agonists in the treatment of stable chronic obstructive pulmonary disease
by: Decramer ML, et al.
Published: (2013-01-01)

Efficacy and safety of the long-acting β2-agonist olodaterol over 4 weeks in Japanese patients with chronic obstructive pulmonary disease
by: Ichinose M, et al.
Published: (2015-08-01)

Review: Safety of long-acting β2 -agonists in the treatment of asthma
by: Mario Cazzola, et al.
Published: (2007-10-01)

Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents
by: Fabbri Leonardo M, et al.
Published: (2010-10-01)

Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis
by: Donohue JF, et al.
Published: (2017-01-01)

Clinical pharmacokinetics of AZD3199, an inhaled ultra-long-acting β2-adrenoreceptor agonist (uLABA)
by: Bjermer L, et al.
Published: (2015-02-01)

Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol
by: Roskell NS, et al.
Published: (2014-07-01)

Assessment of Health Outcomes for Chronic Obstructive Pulmonary Disease (COPD) Patients Using Long-acting Beta2- Agonists
by: Guo, Jing
Published: (2013)

New FDA safety warnings for LABAs: A call for asthma guidelines revisit for solo beta agonist
by: Koshak Emad
Published: (2010-01-01)

Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials
by: Sanjay Sethi, et al.
Published: (2020-02-01)

An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease
by: Cazzola M, et al.
Published: (2021-08-01)

Risk of pneumonia with inhaled corticosteroid/long-acting β2 agonist therapy in chronic obstructive pulmonary disease: a cluster analysis
by: DiSantostefano RL, et al.
Published: (2014-05-01)

Management of chronic obstructive pulmonary disease: Insights into patient profile – Use of inhaled corticosteroids/long-acting β2-Agonists or long-acting β2-agonists/long-acting muscarinic antagonists
by: Nevin Kishore, et al.
Published: (2020-01-01)

Safety aspect of β2-agonists in chronic obstructive pulmonary disease
by: Whale, Christopher Ian
Published: (2009)

Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease
by: Ora J, et al.
Published: (2020-12-01)

Beta-Adrenergic Receptors and Mechanisms in Asthma: The New Long-Acting Beta-Agonists
by: Robert G Townley
Published: (1996-01-01)

Long-Acting Beta Agonists Enhance Allergic Airway Disease.
by: John M Knight, et al.
Published: (2015-01-01)

Efficacy and Safety of LAMA/LABA Fixed-Dose Combination Therapies in Chronic Obstructive Pulmonary Disease: A Systematic Review of Direct and Indirect Treatment Comparisons
by: Hurst JR, et al.
Published: (2020-07-01)

Efficacy and safety of conventional long acting β2- agonists: systematic review and meta-analysis
by: Reza Karbasi-Afshar, et al.
Published: (2016-04-01)

Efficacy and safety of the CRTh2 antagonist AZD1981 as add-on therapy to inhaled corticosteroids and long-acting β2-agonists in patients with atopic asthma
by: Bateman ED, et al.
Published: (2018-05-01)

Effect of background long-acting beta2-agonist therapy on the efficacy and safety of a novel, nebulized glycopyrrolate in subjects with moderate-to-very-severe COPD
by: Kerwin EM, et al.
Published: (2018-09-01)

Safety of beta-agonists with different duration of action in patients with arterial hypertension and broncho-obstructive diseases
by: Yu A Dolgusheva, et al.
Published: (2015-03-01)

Short-Acting Beta-Agonist Research: A Perspective
by: Malcolm R Sears
Published: (2001-01-01)

Impact of beta2-agonists, beta-blockers, and their combination on cardiac function in elderly male patients with chronic obstructive pulmonary disease
by: Zeng LH, et al.
Published: (2013-09-01)

A randomized controlled trial of long-acting muscarinic antagonist and long-acting β2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease
by: Masato Muraki, et al.
Published: (2021-01-01)

Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine
by: Paola Rogliani, et al.
Published: (2019-05-01)

Profiling the bronchodilator effects of the novel ultra-long-acting β-agonist indacaterol against established treatments in chronic obstructive pulmonary disease
by: Claus Vogelmeier, et al.
Published: (2011-10-01)

Loss of Asthma Control in Pediatric Patients after Discontinuation of Long-Acting Beta-Agonists
by: Adrian R. O'Hagan, et al.
Published: (2012-01-01)

The Effect of Polymorphisms of Beta2 Adrenoceptors on Response to Long-acting Beta2 Agonists in Iranian Asthmatic Patients
by: Fatemeh Soleimani, et al.
Published: (2013-12-01)

The divergent opinions of regulatory authorities on roflumilast are puzzling but we need new drugs for treating chronic obstructive pulmonary disease
by: Mario Cazzola
Published: (2010-08-01)

Comparison of efficacy of long-acting bronchodilators in emphysema dominant and emphysema nondominant chronic obstructive pulmonary disease
by: Fujimoto K, et al.
Published: (2011-04-01)

Comparative efficacy of inhaled corticosteroid and long-acting beta agonist combinations in preventing COPD exacerbations: a Bayesian network meta-analysis
by: Oba Y, et al.
Published: (2014-05-01)

Molecular & pharmacological approach for the optimisation of combination therapy of a long-acting β2 agonist and a corticosteroid in chronic obstructive pulmonary disease
by: Rossios, Christos
Published: (2010)

Triple Therapy Versus Dual Bronchodilation and Inhaled Corticosteroids/Long-Acting β-Agonists in COPD: Accumulating Evidence from Network Meta-Analyses
by: Mario Cazzola, et al.
Published: (2019-11-01)

Tolerance to bronchodilation during treatment with long-acting beta-agonists, a randomised controlled trial
by: Hancox Robert J, et al.
Published: (2005-09-01)

Β2-agonist in patients with chronic obstructive pulmonary disease
by: N. N. Mescheryakova
Published: (2014-12-01)

Long-acting maintenance pharmacotherapy in chronic obstructive pulmonary disease
by: Eneida M. Harrison, et al.
Published: (2019-01-01)

Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease
by: Bateman Eric D, et al.
Published: (2011-04-01)